Illumina Inc Cash Flow Conversion Efficiency

Latest as of December 2025: 0.104x

Illumina Inc cash flow conversion efficiency. Based on the latest financial reports, Illumina Inc (ILMN) has a cash flow conversion efficiency ratio of 0.104x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($321.00 Million) by net assets ($3.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Illumina Inc for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of Illumina Inc (1999–2025)

Cash flow conversion efficiency of Illumina Inc from 1999 to 2025. This chart illustrates how Illumina Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Illumina Inc for real-time trading data and today's change.

Illumina Inc Cash Flow Conversion Ratio Explained

Illumina Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Illumina Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Illumina Inc ranked by their cash flow conversion efficiency. Review Illumina Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Company Cash Flow Conversion Efficiency
Essity AB (publ)
ST:ESSITY-B
0.033x
Dollar Tree Inc
NASDAQ:DLTR
0.328x
China Jushi Co Ltd
SHG:600176
0.066x
Huatai Securities Co Ltd
SHG:601688
0.170x
SAIC Motor Corp Ltd
SHG:600104
0.041x
TECHTRONIC INDS ADR/5
F:TIB
N/A
China Minsheng Banking Corp Ltd
SHG:600016
0.014x
Samvardhana Motherson International Limited
NSE:MOTHERSON
0.078x

Annual Cash Flow Conversion Efficiency for Illumina Inc (1999–2025)

The table below shows the annual cash flow conversion efficiency of Illumina Inc from 1999 to 2025. Also see ILMN current and non-current assets for a full breakdown of the balance sheet.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $3.08 Billion $1.08 Billion 0.350x -0.78%
2024-12-31 $2.37 Billion $837.00 Million 0.353x +323.93%
2023-12-31 $5.75 Billion $478.00 Million 0.083x +40.07%
2022-12-31 $6.60 Billion $392.00 Million 0.059x +17.06%
2021-12-31 $10.74 Billion $545.00 Million 0.051x -77.94%
2020-12-31 $4.69 Billion $1.08 Billion 0.230x +0.99%
2019-12-31 $4.61 Billion $1.05 Billion 0.228x -22.07%
2018-12-31 $3.91 Billion $1.14 Billion 0.292x -0.79%
2017-12-31 $2.97 Billion $875.00 Million 0.295x -0.76%
2016-12-31 $2.31 Billion $687.24 Million 0.297x -15.31%
2015-12-31 $1.88 Billion $659.60 Million 0.351x +2.17%
2014-12-31 $1.46 Billion $501.27 Million 0.343x +36.17%
2013-12-31 $1.53 Billion $386.42 Million 0.252x +13.86%
2012-12-31 $1.32 Billion $291.87 Million 0.221x -33.54%
2011-12-31 $1.08 Billion $358.14 Million 0.333x +46.36%
2010-12-31 $1.20 Billion $272.57 Million 0.228x +12.72%
2009-12-31 $864.25 Million $174.50 Million 0.202x +94.96%
2008-12-31 $848.60 Million $87.88 Million 0.104x -24.27%
2007-12-31 $411.68 Million $56.29 Million 0.137x -13.28%
2006-12-31 $247.34 Million $39.00 Million 0.158x +226.90%
2005-12-31 $72.50 Million $-9.01 Million -0.124x +54.13%
2004-12-31 $72.26 Million $-19.57 Million -0.271x +29.69%
2003-12-31 $47.39 Million $-18.26 Million -0.385x -7.99%
2002-12-31 $71.74 Million $-25.59 Million -0.357x -248.70%
2001-12-31 $106.79 Million $-10.93 Million -0.102x +11.29%
2000-12-31 $124.10 Million $-14.31 Million -0.115x -27.07%
1999-12-31 $32.03 Million $-2.91 Million -0.091x --

About Illumina Inc

NASDAQ:ILMN USA Diagnostics & Research
Market Cap
$44.13 Billion
Market Cap Rank
#1361 Global
#553 in USA
Share Price
$288.79
Change (1 day)
+3.33%
52-Week Range
$99.01 - $293.69
All Time High
$510.54
About

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and … Read more